Meta-Analysis of the Effectiveness of Sofosbuvir-Based Regimens in Treating Hepatitis C Genotype 3
DOI:
https://doi.org/10.51985/JBUMDC2024319Keywords:
effectiveness, hepatitis C virus, meta-analysis, SofosbuvirAbstract
Hepatitis C virus (HCV) is an RNA virus with seven primary genotypes. It is highly prevalent in Pakistan, especially genotype 3. HCV infection can progress to a chronic state with further complications. Direct-acting antiviral agents (DAAV) were introduced in 2014 as a treatment option, some of which include Sofosbuvir (SOF), Daclatasvir (DCV), Velpatasvir (VEL) and Ribavirin (RV). This meta-analysis was performed to outline the treatment response and efficacy of DAAV in HCV infected patients.
We systematically searched PubMed, Web of Science, MEDLINE, and Google Scholar for studies from January 2019 to December 2023. The studies selected met the criteria of patients having chronic HCV infection (genotype 3) and either compensated cirrhosis or decompensated chronic liver disease. Treatment regimens with DAAV specifically were included. The primary outcomes [sustained viral response (SVR), rapid virological response (RVR), end-of-treatment response (ETR)] were highlighted to assess treatment response.
The studies proved that the use of direct-acting antiviral agents in different combinations was very effective against HCV infection with minimal side-effects.
References
Negro F, Alberti A. The global health burden of hepatitis C
virus infection. Liver Int. 2011 Jul;31 Suppl 2:1–3 DOI:10.1111
/j.1478-3231.2011.02537.x.
Ahmed T, Ahmad OHA, Bilal M, Alam S, Zaheer S, Gul Z.
Comparison of Efficacy of Sofosbuvir & Daclatasvir with
Sofosbuvir and Velpatasvir in Achieving SVR in Patients of
Chronic Hepatitis C with Genotype 3. Pakistan Journal of
Medical & Health Sciences. 2022 Jun 25;16(04):1155–1155
DOI:10.53350/pjmhs221641155.
HaqqiAleena, MunirRimsha, KhalidMuhammad,
KhurramMuhammad, ZaidMuhammad, AliMuhammad, et
al. Prevalence of Hepatitis C Virus Genotypes in Pakistan:
Current Scenario and Review of Literature. Viral Immunology
[Internet]. 2019 Nov 7 [cited 2023 Oct 15]; DOI:10.1089/vim.
0058. Available from: https://www.liebertpub. com
/doi/10.1089/vim.2019.0058
Shah I, Ahmad W, Qadir A, Muhammad I, Islam M, Shah M,
et al. Efficacy and Safety of Sofosbuvir and Velpatasvir
Combination for the Treatment of Chronic Hepatitis C in
Patients With or Without Cirrhosis. Cureus [Internet]. 2021
Nov 20 [cited 2023 Sep 21]; DOI:10.7759/cureus.19768.
The epidemiology of hepatitis C virus in Pakistan: systematic
review and meta-analyses | Royal Society Open Science
[Internet]. [cited 2023 Oct 28]. Available from:
https://royalsociety publishing .org/doi/full/10.1098 /rsos.
Abbas: Prevalence and mode of spread of hepatitis... - Google
Scholar [Internet]. [cited 2023 Oct 28].
Aslam: Association between smallpox vaccination and... -
Google Scholar [Internet]. [cited 2023 Oct 28].
High prevalence of hepatitis C virus infection in the largest
province of Pakistan - IDREES - 2008 - Journal of Digestive
Diseases - Wiley Online Library [Internet]. [cited 2023 Oct
.
Hashmi A, Saleem K, Soomro JA. Prevalence and Factors
Associated with Hepatitis C Virus Seropositivity in Female
Individuals in Islamabad, Pakistan. Int J Prev Med. 2010;1(4):
–6.
Butt N, Anoshia, Khan MA, Akbar A. Effectiveness of
Sofosbuvir and Daclatasvir in treatment of Hepatitis-C: An
experience of tertiary care hospital in Karachi. Pak J Med
Sci. 2021;37(7):2014–9 DOI:10.12669/pjms.37.7.4627.
Moussalli J, Opolon P, Poynard T. Management of hepatitis
C. Journal of Viral Hepatitis. 1998;5(2):73–82
DOI:10.1046/j.1365-2893.1998.00086.x.
Seeff LB. Natural history of viral hepatitis, type C. Semin
Gastrointest Dis. 1995 Jan;6(1):20–7.
Bisceglie AMD. Hepatitis C and Hepatocellular Carcinoma.
Semin Liver Dis. 1995;15(1):64–9 DOI:10.1055/s-2007-
An Assay for Circulating Antibodies to a Major Etiologic
Virus of Human Non-A, Non-B Hepatitis | Science [Internet].
[cited 2023 Oct 28]. Available from: https://www.science.org
/doi/abs/10.1126/science.2496467
Hepatitis C Virus Infection | NEJM [Internet]. [cited 2023
Oct 28]. Available from: https://www.nejm.org/doi
/full/10.1056/nejm200107053450107
Riaz HA, Nishwa DE, Fatima A, Wahid B, Ali A, Kumari B,
et al. Risk of adverse outcomes following treatment with
direct acting antiviral drugs in HCV infected patients with
liver cirrhosis. Heliyon [Internet]. 2023 May 1 [cited 2023
Oct 16];9(5) DOI:10.1016/j.heliyon.2023.e16169.
Khan A, Nadir A, Mushtaq MH, Junaid K, Khan AM, Ali H,
et al. Molecular epidemiology and genotype distribution of
hepatitis C in Pakistan; a multicenter cross-sectional study.
Infection, Genetics and Evolution. 2020 Oct 1;84:104372
DOI:10.1016/j.meegid.2020.104372.
Ramia S, Eid-Fares J. Distribution of hepatitis C virus
genotypes in the Middle East. International Journal of Infectious
Diseases. 2006 Jul 1;10(4):272–7 DOI:10.1016/j.ijid.
07.008.
Waqas K, Saddiqa A, Naqvi SZH, Qureshi JA, Dar OA, Butt
MS, et al. Evaluation of Direct-Acting Antiviral Drugs for
Hepatitis C Genotype 3 Patients from ages 30-50 years in
Sialkot, Pakistan. 2022;18(12).
Shah HA, Jafri W, Malik I, Prescott L, Simmonds P. Hepatitis
C virus (HCV) genotypes and chronic liver disease in Pakistan.
J Gastroenterol Hepatol. 1997 Nov;12(11):758–61 DOI:10.
/j.1440-1746.1997.tb00366.x.
Idrees M, Riazuddin S. Frequency distribution of hepatitis C
virus genotypes in different geographical regions of Pakistan
and their possible routes of transmission. BMC Infect Dis.
May 23;8:69 DOI:10.1186/1471-2334-8-69.
Bakr AA, Sarwar S, Aslam N, Ghias M, Mehfooz I. SofosbuvirVelpatasvir for Chronic Hepatitis C Virus-Infected Children
and Young Adults: Efficacy and Safety. Annals of King Edward
Medical University. 2023 Sep 2;29(2):118–22 DOI:10.21649
/akemu.v29i2.5433.
Munir N, Bajwa H, Aftab M, Bibi A, Mahmood Z, Shoukat
M, et al. Safety Status of Interferon-free All-oral Direct-acting
Antiviral Agents (DAAs) to treat HCV patients in Tertiary
Care Hospital of Faisalabad-Pakistan. 2023 May 4;93–100
DOI:10.52587/njhms.v3i2.26.
McPhee F. Developments in the treatment of HCV genotype
infection. Expert Review of Anti-infective Therapy. 2019
Oct 3;17(10):775–85 DOI:10.1080/14787210.2019.1676730.
Jawad M, Attaullah S, Khan S, Ullah F, Zahid M, Saeed F,
et al. Safety and efficacy of Sofosbuvir therapy in chronic
hepatitis C patients of Peshawar, Khyber Pakhtunkhwa,
Pakistan. Songklanakarin Journal of Science and Technology.
Jul 18;44:683–9 DOI:10.14456/sjst-psu.2022.93.
Khan FA, Ahmad M, Khan I, Khan AAT, Kashif M, Malik T.
Efficacy of Daclatasvir with Sofosbuvir for Treating Chronic
Hepatitis C Genotype 3. Pakistan Journal of Medical & Health
Sciences. 2022 Jun 1;16(05):240–240 DOI:10.53350/
pjmhs22165240.
Malghani WS, Chaudhary FMD, Shahid M, Tameez-ud-din
A, Malik R, Din ATU. Safety and Efficacy of Daclatasvir
with Sofosbuvir and Ribavirin in Hepatitis C Virus Infection:
A Real World Experience from South Punjab,DOI:10.1101/
10.23.21265410.
Haider SA, Ahmad B, Ali S, Haider A, Bashir S, Mahmood
N. Sofosbuvir and Ribavirin Combination Therapy Response
in Various Hepatitis C Virus Genotypes in Peshawar, Khyber
Pakhtunkhwa. Jundishapur J Microbiol [Internet]. 2020 [cited
Oct 16];13(6) DOI:10.5812/jjm.99625.
Younas S, Mukhtar H, Gohar UF, Alsrhani A, Alzahrani B,
Junaid K, et al. Diagnostic approach to elucidate the efficacy
and side effects of direct-acting antivirals in HCV infected
patients. The Journal of Infection in Developing Countries.
Oct 31;15(10):1489–96 DOI:10.3855/jidc.12912.
The natural course of HCV infection and the need for treatment
[Internet]. [cited 2023 Oct 16].
Mushtaq S, Akhter TS, Khan A, Sohail A, Khan A, Manzoor
S. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir
and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected
Patients: Real-World Outcomes From Pakistan. Frontiers in
Pharmacology [Internet]. 2020 [cited 2023 Oct 15];11.
Akhter TS, Umar M, Khaar H-T-B, Aslam F, Nisar G, Naseer
A, et al. Sofosbuvir For The Treatment Of Hepatitis C Genotype
Infected Patients In Pakistan. Journal of Ayub Medical
College Abbottabad. 2017 Feb 1;28(4 Sup):884–9.
Sarwar S, Tarique S, Aleem A, Khan AA. Effect of adding
daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis
C: real-world experience in Pakistan. European Journal of
Gastroenterology & Hepatology. 2019 Aug 1;31(8):1035–9
DOI:10.1097/MEG.0000000000001376.
EASL Recommendations on Treatment of Hepatitis C 2016.
Journal of Hepatology. 2017 Jan 1;66(1):153–94 DOI:10.1016/j
.jhep.2016.09.001.
Ullah Z, Khan SZ, Khan H, Lodhi H. Efficacy of sofosbuvir
and daclatasvir in achieving the end treatment response and
sustained viral response in patients infected with hepatitis C
Virus Genotype. Pakistan Armed Forces Medical Journal.
;72(3):1074–7.
Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI,
Dore GJ, et al. Sofosbuvir Plus Velpatasvir Combination
Therapy for Treatment-Experienced Patients With Genotype
or 3 Hepatitis C Virus Infection. Ann Intern Med. 2015
Dec;163(11):809–17 DOI:10.7326/M15-1014.
Sohail Hussain M, Sm Qamrul Arfin M, Imtiaz Begum M,
Syed Ali Raza M, Tauseef Ahmed M, Jamil Muqtadir M.
Efficacy Of Sofosbuvir In Combination With Daclatasvir For
The Treatment Of Hepatitis C Genotype 3a Patients In A
Tertiary Care Center In Pakistan. J Popl Ther Clin Pharmacol.
Sep 30;30(17):2219–24 DOI:10.53555/jptcp .v30i17
.2963.
Advanced liver fibrosis effects on the response to sofosbuvirbased antiviral therapies for chronic hepatitis C - Morio -
- Journal of Medical Virology - Wiley Online Library
[Internet]. [cited 2023 Oct 28].
Follow-up of sustained virological responders with hepatitis
C and advanced liver disease after interferon/ribavirin-free
treatment - Kozbial - 2018 - Liver International - Wiley Online
Library [Internet]. [cited 2023 Oct 28
Petruzziello A, Marigliano S, Loquercio G, Cozzolino A,
Cacciapuoti C. Global epidemiology of hepatitis C virus
infection: An up-date of the distribution and circulation of
hepatitis C virus genotypes. World J Gastroenterol. 2016 Sep
;22(34):7824–40 DOI:10.3748/wjg.v22.i34.7824.
Kanwal F, Singal AG. Surveillance for Hepatocellular
Carcinoma: Current Best Practice and Future Direction.
Gastroenterology. 2019 Jul 1;157(1):54–64 DOI:10.1053/j
.gastro.2019.02.049.
Mari A, Khoso MM, Saeed A, Ahmed S, Mari K, Hussain R.
Determination of Real-world Single-center Experience with
Direct-acting Antivirals for Improvement of Liver Fibrosis
after Chronic Hepatitis C Treatment. Journal of Pharmaceutical
Research International. 2022 Feb 23;28–35 DOI:10.9734/jpri/
/v34i14B35680.
Kazmi S, Farooqi H, Sohail U, Zaidi SH, Majeed N, Firdus
S. Sustained virological response (SVR) and safety of two
direct acting anti-viral (DAA) combination therapies in Chronic
Hepatitis-C infected patients of Lahore, Pakistan. A
Randomized Controlled Trial: SVR and DAA Therapies in
Hepatitis-C Infected Patients. Pakistan Journal of Health
Sciences. 2022 Nov 30;135–9 DOI:10.54393/pjhs.v3i06.294.
Sajjad SF, Ahmed W uddin, Alam SE. Sofosbuvir and Ribavirin
in Chronic Hepatitis C Virus Patients with No Response or
Relapse with Interferon Therapy. Journal of the Dow University
of Health Sciences (JDUHS). 2020 Dec 17;14(3):139–43
DOI:10.36570/jduhs.2020.3.856.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Hafsa Siddique, Syed Sufyan Tariq, Syed Parvez Asghar, Muhammad Faisal Fahim
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
